Stock Events

Stock Events

Regencell Bioscience 

$28.28
141
+$3.29+13.17% Monday 21:00

Statistics

Day High
29.99
Day Low
24.5
52W High
83.6
52W Low
0.09
Volume
313,553
Avg. Volume
479,321
Mkt Cap
13.98B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Feb 18
$0.01
Dec 17
$0.01
Sep 17
$0.01
Jun 17
$0.01
Mar 17
$0.01
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

31OctExpected
Q2 2020
Q3 2020
Q1 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
-33.38
-22.25
-11.13
0
Expected EPS
0
Actual EPS
-0.3

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.17MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that overlaps with Regencell's focus on regenerative medicine, making them direct competitors in the biotech innovation space.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, directly competing with Regencell in the development of treatments for genetic diseases and conditions.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading developer of CRISPR/Cas9 gene-editing therapies, competing with Regencell in the race to develop genetic treatments.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with Regencell in the development of novel genetic treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Regencell in the broader biotech market.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other serious diseases, competing with Regencell in the market for innovative therapeutic solutions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Regencell in the field of genetic medicine.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics focuses on precision genetic medicines using base editing, a form of gene editing, placing it in direct competition with Regencell's gene-based therapies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, a large pharmaceutical company, has been expanding its investment in biotechnology and gene therapy, making it a competitor to Regencell in the broader market for innovative treatments.

About

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Show more...
CEO
Mr. Yat-Gai Au
Employees
12
Country
KY
ISIN
KYG7487R1002

Listings

XNAS
US
RGC
BOATS
BOATS
RGC.BOATS

0 Comments

Share your thoughts

FAQ

What is Regencell Bioscience stock price today?▼
The current price of RGC is $28.28 USD — it has increased by +13.17% in the past 24 hours. Watch Regencell Bioscience stock price performance more closely on the chart.
What is Regencell Bioscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Regencell Bioscience stocks are traded under the ticker RGC.
Is Regencell Bioscience stock price growing?▼
RGC stock has fallen by -11.76% compared to the previous week, the month change is a +37.68% rise, over the last year Regencell Bioscience has showed a +28,105.77% increase.
What is Regencell Bioscience market cap?▼
Today Regencell Bioscience has the market capitalization of 13.98B
What were Regencell Bioscience earnings last quarter?▼
RGC earnings for the last quarter are -0.3 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regencell Bioscience revenue for the last year?▼
Regencell Bioscience revenue for the last year amounts to 0 USD.
What is Regencell Bioscience net income for the last year?▼
RGC net income for the last year is -7.17M USD.
Does Regencell Bioscience pay dividends?▼
Yes, RGC dividends are paid quarterly. The last dividend per share was 0.01 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Regencell Bioscience have?▼
As of February 03, 2026, the company has 12 employees.
In which sector is Regencell Bioscience located?▼
Regencell Bioscience operates in the Health Care sector.
When did Regencell Bioscience complete a stock split?▼
The last stock split for Regencell Bioscience was on June 16, 2025 with a ratio of 38:1.
Where is Regencell Bioscience headquartered?▼
Regencell Bioscience is headquartered in Causeway Bay, KY.